The field of oncology has experienced a significant wave of innovation in next generation of T-cell […]
In this episode of ClearView Convos, Sam Ulin is joined by Kelsey Yardumian and David Konciak […]
In today’s increasingly competitive landscape, biopharma manufacturers must strategically prepare for launch. ClearView spoke with 11 […]
Real talk on launch strategy— in this episode of ClearView Convos, @Jessica Lee and @Alex Lehrman […]
In this episode, Sam Ulin, Debbie Zhuang, and Matthew Murphy dive into the strategic heart of […]
Yesterday we recorded a follow-up to Episode 2, diving deeper into evolving vaccine dynamics after RFK […]
Episode 2 digs into the regulatory uncertainty in the vaccine world – what we know, what […]
Sam Ulin moderates a discussion with Pricing & Market Access Partners Mike Rizzo and Rishi Dalsania […]
An evolving vaccine market fueled by rapid innovation has shifted channels for vaccine distribution and administration, […]
As companies with global commercialization aspirations move from clinical development to launch, it becomes important to […]
BIO-Europe Spring connects Europe’s top innovation centers with the global life sciences industry to cultivate thriving […]
ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI to Advance Next-Generation Biomedical AI Platform ClearView […]
From a population health perspective, the need to more effectively treat neurological dysfunction is pressing, as […]
GLP-1 receptor agonists are already reshaping people and healthcare systems for the management of obesity. Treatment paradigms in cardiovascular disease, sleep apnea and MASH are set to be disrupted, but it is not all gravy; weight loss post GLP-1s is often not maintained and not everyone can tolerate their side effects. We share our perspectives on the outlook for the space, including some of the implications for biopharma, service providers and investors.
Radioligand therapies (RLTs) are an emerging class of targeted therapies that could transform the way some cancers are treated. The RLT market is expected to grow significantly over the course of this decade, however several challenges will need to be overcome if the market is to achieve its full potential. In this white paper we consider the scientific, clinical, and commercial requirements for success.
Treatment paradigms in oncology are constantly evolving with more precise and efficacious therapies. One modality with strong potential are mRNA therapeutics which represent a significant growth area and could transform the way some cancers are treated. In this white paper we explore the potential for mRNA to transform the oncology landscape, considering the scientific, clinical and commercial requirements for success
How life sciences companies can use affiliations data to track non-traditional healthcare services.
Psychedelic-assisted therapies with MDMA and psilocybin are poised to transform the treatment options for a variety […]
An exploration within the growing CDMO space of manufacturing capabilities and efficiencies that support development of […]
This August, ClearView Healthcare Partners had the pleasure of welcoming Laurel Sweeney and Andy Molnar for a panel discussion on the challenges and strategic approaches to secure reimbursement for digital health technologies – thank you to both for participating!
• GHO partnering with existing management team to accelerate global growth
• ClearView positioned as market leader in an industry experiencing strong tailwinds
• Management to pursue international markets and broaden service offering, leveraging GHO’s unparalleled sector expertise